TrialThe AAPS journal2013

Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Rui Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.